Status:
UNKNOWN
Delta Radiomics for Liver Function Evaluation
Lead Sponsor:
Zhujiang Hospital
Conditions:
Chronic Liver Disease
Eligibility:
All Genders
18-70 years
Brief Summary
To evaluate the feasibility and efficacy of delta radiomics-derived index based on Gd-EOB-DTPA enhanced MRI as a new imaging biomarker for the quantitative assessment of liver function.
Detailed Description
Delta radiomics is a novel concept proposed on the basis of radiomics. It can be used to evaluate the dynamic changes of imaging features in the time dimension, reflecting functional information of th...
Eligibility Criteria
Inclusion
- 18-70 years old, no gender limit.
- Patients with chronic liver disease and different degrees of liver damage (Child-Pugh A, B and C) and healthy controls.
- No history of liver-related surgery (except for cholecystectomy).
- No cardiopulmonary diseases or other diseases which may impair liver function.
- Agree to participate in the study and provide written informed consent.
Exclusion
- Alcoholic hepatitis, non-alcoholic fatty liver disease, or autoimmune hepatitis.
- Liver tumors or metastasis or other extraheptic tumor.
- Splenectomy or other cases where the spleen is absent.
- Chronic kidney disease, renal damage.
- Allergy to contrast agents or other conditions that cannot undergo Gd-EOB-DTPA enhanced MRI exam.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05296434
Start Date
April 1 2022
End Date
December 31 2022
Last Update
March 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Department of Hepatobiliary Surgery, Zhujiang Hospital
Guangzhou, Guangdong, China, 510280